MA26961A1 - Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose - Google Patents

Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose

Info

Publication number
MA26961A1
MA26961A1 MA27159A MA27159A MA26961A1 MA 26961 A1 MA26961 A1 MA 26961A1 MA 27159 A MA27159 A MA 27159A MA 27159 A MA27159 A MA 27159A MA 26961 A1 MA26961 A1 MA 26961A1
Authority
MA
Morocco
Prior art keywords
bone
loss
receptors
osteoporosis
relates
Prior art date
Application number
MA27159A
Other languages
English (en)
Inventor
Kimberly O'keefe Cameron
Bruce Allen Lefker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26961A1 publication Critical patent/MA26961A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DEPOSANT Société dite: PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 27 Novembre 2000 60/253,275 Voir en annexe le titre de l'invention et le texte de l'abrégé Agonistes sélectifs des récepteurs EP4 pour le traitement de 1'ostéoporose L'invention concerne des agonistes de prostaglandines sélectives des récepteurs EP4, de formule (I), dans laquelle R2, X, Z et Q répondent aux définitions figurant dans le présent mémoire. La présente invention concerne également des compositions pharmaceutiques contenant ces composés. La présente invention concerne également des méthodes de traitement d'affections qui comportent une faible masse osseuse, en particulier 1'ostéoporose, la fragilité, une fracture ostéoporotique, un défaut osseux, la perte de tissu osseux idiopathique de l'enfant, une perte d'os alvéolaire, une perte d'os mandibulaire, une fracture d'un os, une ostéotomie, une perte de tissu osseux associée à la périodontite ou une incarnation prostétique, chez un mammifère, comprenant l'administration de ces composés.
MA27159A 2000-11-27 2003-05-13 Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose MA26961A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25327500P 2000-11-27 2000-11-27

Publications (1)

Publication Number Publication Date
MA26961A1 true MA26961A1 (fr) 2004-12-20

Family

ID=22959588

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27159A MA26961A1 (fr) 2000-11-27 2003-05-13 Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose

Country Status (41)

Country Link
US (3) US6552067B2 (fr)
EP (1) EP1339678B1 (fr)
JP (2) JP3984164B2 (fr)
KR (1) KR20030053063A (fr)
CN (1) CN1476429A (fr)
AR (1) AR035074A1 (fr)
AT (1) ATE374182T1 (fr)
AU (1) AU2002210848A1 (fr)
BG (1) BG107697A (fr)
BR (1) BR0115687A (fr)
CA (1) CA2429850C (fr)
CY (1) CY1106976T1 (fr)
CZ (1) CZ20031257A3 (fr)
DE (1) DE60130675T2 (fr)
DK (1) DK1339678T3 (fr)
EA (1) EA200300379A1 (fr)
EC (1) ECSP034623A (fr)
EE (1) EE200300246A (fr)
ES (1) ES2291361T3 (fr)
GT (2) GT200100238A (fr)
HN (1) HN2001000266A (fr)
HU (1) HUP0400807A2 (fr)
IL (1) IL155368A0 (fr)
IS (1) IS6775A (fr)
MA (1) MA26961A1 (fr)
MX (1) MXPA03004623A (fr)
NO (1) NO20032360L (fr)
NZ (1) NZ525164A (fr)
OA (1) OA12533A (fr)
PA (1) PA8533901A1 (fr)
PE (1) PE20020637A1 (fr)
PL (1) PL362030A1 (fr)
PT (1) PT1339678E (fr)
SI (1) SI1339678T1 (fr)
SK (1) SK5562003A3 (fr)
SV (1) SV2003000746A (fr)
TN (1) TNSN01166A1 (fr)
TW (1) TW200424170A (fr)
UY (1) UY27038A1 (fr)
WO (1) WO2002042268A2 (fr)
ZA (1) ZA200302803B (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12533A (en) * 2000-11-27 2006-06-05 Pfizer Prod Inc Ep4 receptor selective agonists in the treatment of osteoporosis.
CA2451392A1 (fr) 2001-07-16 2003-01-30 F. Hoffmann-La Roche Ag Analogues de la prostaglandine utilises comme agonistes du recepteur ep4
CN100371322C (zh) * 2001-07-16 2008-02-27 霍夫曼-拉罗奇有限公司 作为前列腺素类化合物激动剂的2-吡咯烷酮衍生物
EP2255829A3 (fr) 2001-07-23 2012-03-28 Ono Pharmaceutical Co., Ltd. Composition pharmaceutique contenant un agoniste de EP4 en tant que principe actif destiné aux maladies associées à une perte de la masse osseuse
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
AU2003211574A1 (en) * 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
WO2003077910A1 (fr) * 2002-03-18 2003-09-25 Pfizer Products Inc. Procedes de traitement au moyen d'agonistes selectifs du recepteur ep4
EP1490055A1 (fr) * 2002-03-18 2004-12-29 Pfizer Products Inc. Utilisation d'agonistes du recepteur ep4 selectif pour le traitement de l'insuffisance hepatique, de la perte de la permeabilite du canal arteriel, du glaucome ou de l'hypertension oculaire
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
WO2003103664A1 (fr) * 2002-06-06 2003-12-18 Merck Frosst Canada & Co. Derives d'imidazolidine-2-one disubstitues en 1,5 utiles en tant qu'agonistes du recepteur ep4 dans le traitement de troubles oculaires et de maladies osseuses
AU2003233729B2 (en) * 2002-06-06 2007-10-04 Merck Frosst Canada Ltd 1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma
JP4754820B2 (ja) * 2002-06-10 2011-08-24 メルク セローノ ソシエテ アノニム プロスタグランジン作動薬としてのγラクタムおよびその使用
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
ES2584606T3 (es) 2002-10-10 2016-09-28 Ono Pharmaceutical Co., Ltd. Microesferas que comprenden ONO-1301
WO2004037813A1 (fr) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Derives de pyrrolidine-2-one en tant qu'agonistes du recepteur ep4
AU2003287481B2 (en) 2002-11-08 2009-04-23 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CA2511255C (fr) * 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag Derives de 2-piperidone agonistes de la prostaglandine
US7256211B1 (en) * 2003-01-21 2007-08-14 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medical use thereof
ES2305779T3 (es) 2003-03-03 2008-11-01 Laboratoires Serono Sa Derivados de g-lactama como agonistas de prostaglandinas.
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
CA2529123A1 (fr) 2003-07-18 2005-02-10 Applied Research Systems Ars Holding N.V. Derives d'hydrazides constituant des modulateurs des recepteurs de la prostaglandine
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
AU2004268012B2 (en) 2003-09-02 2008-11-20 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
DE602004020079D1 (de) 2003-09-04 2009-04-30 Merck & Co Inc Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
AU2004271978B2 (en) 2003-09-04 2009-02-05 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2005027931A1 (fr) * 2003-09-19 2005-03-31 Pfizer Products Inc. Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un agoniste selectif de ep2 ou ep4
US20070191319A1 (en) * 2003-12-17 2007-08-16 Pfizer Inc. Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
CN1988903A (zh) 2004-07-20 2007-06-27 默克公司 用于治疗高眼压症的眼用组合物
JP4893999B2 (ja) * 2004-10-22 2012-03-07 小野薬品工業株式会社 吸入用医薬組成物
AU2005299473B2 (en) * 2004-10-26 2012-06-28 Allergan, Inc. Therapeutic and delivery methods of prostaglandin EP4 agonists
US7994195B2 (en) * 2004-11-04 2011-08-09 Allergan, Inc. Therapeutic substituted piperidone compounds
WO2006052893A2 (fr) 2004-11-08 2006-05-18 Allergan, Inc. Composes de pyrrolidone substitue therapeutique
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
CN101133037B (zh) * 2005-01-27 2012-05-09 旭化成制药株式会社 六元杂环化合物及其用途
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
US7772392B2 (en) 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
BRPI0611257A2 (pt) * 2005-05-06 2010-08-24 Allergan Inc beta-lactamas substituÍdas e uso em medicina do mesmo
US7893107B2 (en) * 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
KR100598678B1 (ko) * 2006-02-15 2006-07-19 (주)아이앤씨 수직형 대형 폐기물 파쇄기
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
EP2120962A1 (fr) * 2006-12-18 2009-11-25 Allergan, Inc. Procédés et compositions pour traiter des troubles gastro-intestinaux
EP2147672A4 (fr) 2007-05-08 2011-11-02 Nat University Corp Hamamatsu University School Of Medicine Activateur de cellule t cytotoxique comprenant un agoniste ep4
SI2155733T1 (sl) * 2007-05-23 2012-12-31 Allergan, Inc Ciklični laktami za zdravljenje glavkoma ali zvišanega očesnega tlaka
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
WO2010019796A1 (fr) * 2008-08-14 2010-02-18 Chemietek, Llc Dérivés d’amides hétérocycliques en tant qu’antagonistes du récepteur ep4
WO2010116270A1 (fr) 2009-04-10 2010-10-14 Pfizer Inc. Agonistes de ep2/4
WO2011047048A1 (fr) 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Traitement par polythérapie pour infections virales
RU2564414C2 (ru) * 2010-03-08 2015-09-27 Какен Фармасьютикал Ко., Лтд. Новый агонист ер4
CA2738045C (fr) 2010-05-28 2019-02-19 Simon Fraser University Composes conjugues, leurs procedes de fabrication et leurs utilisations
EP2397141A1 (fr) * 2010-06-16 2011-12-21 LEK Pharmaceuticals d.d. Procédé pour la synthèse d'acides aminés beta et leurs dérivés
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
EP2675491A2 (fr) 2011-02-17 2013-12-25 Allergan, Inc. Compositions et procédés améliorés de remplacement de tissu mou
EP2678022A2 (fr) 2011-02-23 2014-01-01 Allergan, Inc. Compositions et procédés de remplacement de tissu mou améliorés
WO2013123272A1 (fr) 2012-02-16 2013-08-22 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
WO2013123275A1 (fr) 2012-02-16 2013-08-22 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
WO2013123270A1 (fr) 2012-02-16 2013-08-22 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
EP2814526B1 (fr) 2012-02-16 2016-11-02 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
WO2014015247A1 (fr) * 2012-07-19 2014-01-23 Cayman Chemical Company, Inc. Composés de difluorolactame comme agonistes sélectifs du récepteur ep4, destinés à être utilisés dans le traitement de maladies et d'affections médiées par ep4
ES2733998T3 (es) 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CA2903314C (fr) 2013-03-15 2023-02-14 Cayman Chemical Company, Inc. Procedes de synthese d'un analogue difluorolactam
PT2989098T (pt) 2013-03-15 2017-08-16 Cayman Chemical Co Inc Compostos de lactama como agonistas selectivos do receptor ep4 para uso no tratamento de doenças e condições mediadas por ep4
KR20160048054A (ko) * 2013-07-19 2016-05-03 카이맨 케미칼 컴파니 인코포레이티드 골 성장의 촉진을 위한 방법, 시스템 및 조성물
KR102456567B1 (ko) 2013-08-09 2022-10-19 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
EP3152188B1 (fr) 2014-06-06 2019-02-13 Allergan, Inc. Nouveaux agonistes des récepteurs ep4 utilisés comme composés thérapeutiques
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
CN107849072B (zh) 2015-06-12 2020-12-15 西蒙弗雷泽大学 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
EP3423067B1 (fr) * 2016-03-04 2025-07-23 The Board of Trustees of the Leland Stanford Junior University Inhibiteurs de la 15-hydroxyprostaglandine déshydrogénase pour la régénération musculaire
CN107011377B (zh) * 2017-05-03 2019-02-26 南通书创药业科技有限公司 一种β-羰基磷酸酯的制备方法
PT3733665T (pt) * 2017-12-25 2022-10-21 Asahi Kasei Pharma Corp Compostos contendo unidade de 2-oxo-1,3,4-tiadiazinan-3-ilo com atividade agonista do recetor ep4
WO2020237096A1 (fr) 2019-05-21 2020-11-26 Ardelyx, Inc. Combinaison pour baisser le phosphate sérique chez un patient

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1158163A (en) 1966-06-15 1969-07-16 Berk Ltd Improvements in or relating to Polymer Compositions
ZA72645B (en) * 1971-03-05 1972-11-29 Upjohn Co Prostaglandin analogs
DE2346706A1 (de) * 1973-09-17 1975-04-03 Hoechst Ag Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (nl) 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
SE423813B (sv) * 1976-08-06 1982-06-07 Pfizer Forfarande for framstellning av 1,5-disubstituerade pyrrolidoner med terapeutiska egenskaper
US4177346A (en) * 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4320136A (en) 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
TW288010B (fr) 1992-03-05 1996-10-11 Pfizer
SE9302334D0 (sv) 1993-07-06 1993-07-06 Ab Astra New compounds
ZA944647B (en) 1993-07-06 1995-01-06 Astra Ab Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
IL113112A (en) 1994-03-28 2000-06-01 Nissan Chemical Ind Ltd Pyridine substituted thiazolidinediones and pharmaceutical compositions comprising them
US5955481A (en) 1994-03-28 1999-09-21 Nissan Chemical Industries, Ltd. Pyridine type thiazolidines
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
AU1444200A (en) 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for inhibiting bone resorption
EP1121133A1 (fr) * 1998-10-15 2001-08-08 Merck & Co., Inc. Methodes de stimulation de la formation osseuse
GEP20043203B (en) * 1999-12-22 2004-03-25 Pfizer Prod Inc EP4 Receptor Selective Agonists in the Treatment of Osteoporosis
IL141120A0 (en) * 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
OA12533A (en) * 2000-11-27 2006-06-05 Pfizer Prod Inc Ep4 receptor selective agonists in the treatment of osteoporosis.
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
PT1339678E (pt) 2007-11-30
EP1339678B1 (fr) 2007-09-26
PE20020637A1 (es) 2002-07-18
CY1106976T1 (el) 2012-09-26
BG107697A (en) 2004-01-30
WO2002042268A3 (fr) 2002-07-25
MXPA03004623A (es) 2003-09-05
PA8533901A1 (es) 2002-11-28
EA200300379A1 (ru) 2003-08-28
JP3984164B2 (ja) 2007-10-03
CN1476429A (zh) 2004-02-18
US6747054B2 (en) 2004-06-08
ATE374182T1 (de) 2007-10-15
PL362030A1 (en) 2004-10-18
TNSN01166A1 (fr) 2005-11-10
GT200100238A (es) 2002-06-26
ES2291361T3 (es) 2008-03-01
KR20030053063A (ko) 2003-06-27
HN2001000266A (es) 2002-01-30
WO2002042268A2 (fr) 2002-05-30
EP1339678A2 (fr) 2003-09-03
DE60130675T2 (de) 2008-01-24
HUP0400807A2 (hu) 2004-07-28
GT200100238AA (es) 2004-05-12
NO20032360L (no) 2003-07-23
SI1339678T1 (sl) 2007-12-31
TW200424170A (en) 2004-11-16
US20030149086A1 (en) 2003-08-07
JP2007197467A (ja) 2007-08-09
AR035074A1 (es) 2004-04-14
IL155368A0 (en) 2003-11-23
CA2429850A1 (fr) 2002-05-30
EE200300246A (et) 2003-10-15
OA12533A (en) 2006-06-05
IS6775A (is) 2003-04-10
ECSP034623A (es) 2003-07-25
US20040259921A1 (en) 2004-12-23
US7192979B2 (en) 2007-03-20
JP2004521869A (ja) 2004-07-22
UY27038A1 (es) 2002-07-31
ZA200302803B (en) 2004-04-13
CZ20031257A3 (cs) 2004-04-14
AU2002210848A1 (en) 2002-06-03
DK1339678T3 (da) 2008-02-04
US20020065308A1 (en) 2002-05-30
CA2429850C (fr) 2008-12-30
BR0115687A (pt) 2003-09-09
NZ525164A (en) 2005-04-29
SV2003000746A (es) 2003-01-13
NO20032360D0 (no) 2003-05-26
US6552067B2 (en) 2003-04-22
SK5562003A3 (en) 2004-08-03
DE60130675D1 (de) 2007-11-08

Similar Documents

Publication Publication Date Title
MA26961A1 (fr) Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose
AP2001002357A0 (en) EP4 receptor selective agonists in the treatment of osteoporosis.
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
MA27009A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA27439A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
BR0110420A (pt) Agonistas muscarìnicos
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
TNSN07022A1 (fr) Derives de pyridine
MA26873A1 (fr) Derives de purine
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
CA2407100A1 (fr) 1-aroyle-piperidinyle benzamidines
MA30999B1 (fr) Composés.
MA30296B1 (fr) Nouvelles amines
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
MA30292B1 (fr) Amines primaires comme inhibiteurs de la renine
DE60225143D1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
Yoo et al. Effect of conditioned medium from preameloblasts on regenerative cellular differentiation of the immature teeth with necrotic pulp and apical periodontitis
DE69919349D1 (de) Piperidinyl- und n-amidinopiperidinyl-derivate
MA27852A1 (fr) Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique
MA30924B1 (fr) Analogues de pyrazoles
IL149544A0 (en) N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR Xa